➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Dow
Harvard Business School

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CT1812

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CT1812?

CT1812 is an investigational drug.

There have been 6 clinical trials for CT1812. The most recent clinical trial was a Phase 1 trial, which was initiated on October 2nd 2018.

The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and [disabled in preview]. The leading clinical trial sponsors are Cognition Therapeutics and [disabled in preview].

There are two US patents protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for CT1812
TitleSponsorPhase
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.Cognition TherapeuticsPhase 2
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's DiseaseCognition TherapeuticsPhase 1
Effect of CT1812 Treatment on Brain Synaptic DensityCognition TherapeuticsPhase 1/Phase 2

See all CT1812 clinical trials

Clinical Trial Summary for CT1812

Top disease conditions for CT1812
Top clinical trial sponsors for CT1812

See all CT1812 clinical trials

US Patents for CT1812

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CT1812   Start Trial Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (Pittsburgh, PA)   Start Trial
CT1812   Start Trial Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (Pittsburgh, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CT1812

Drugname Country Document Number Estimated Expiration Related US Patent
CT1812 Australia 2015210852 2034-01-31   Start Trial
CT1812 Canada 2938212 2034-01-31   Start Trial
CT1812 China 106163516 2034-01-31   Start Trial
CT1812 Denmark 3099296 2034-01-31   Start Trial
CT1812 European Patent Office 3099296 2034-01-31   Start Trial
CT1812 European Patent Office 3498692 2034-01-31   Start Trial
CT1812 Spain 2721001 2034-01-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.